CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners were selected by an independent panel of judges, and the award was presented at a special gala event at the Marriott Copley Place on June 23, 2016.
“On behalf of Collegium’s Board of Directors, I’d like to congratulate Mike on receiving this well-deserved honor,” said Gino Santini, Director of Collegium. “Mike’s extraordinary leadership and entrepreneurial spirit are instrumental to Collegium’s past and future success.”
“I’d like to thank my colleagues from Collegium who have worked tirelessly for many years to address two major epidemics in the United States: chronic pain and prescription opioid abuse. The development and launch of Xtampza™ ER is a tribute to their dedication and commitment to providing solutions for these devastating problems,” said Michael Heffernan, CEO of Collegium.
As a New England award winner, Mike Heffernan is now eligible for consideration for the Entrepreneur of the Year 2016 national program. Award winners in several national categories, as well as the Entrepreneur of the Year National Overall Award winner, will be announced at the Entrepreneur of the Year National Awards gala in Palm Springs, California, on November 19, 2016.
About EY Entrepreneur of the Year
EY Entrepreneur of the Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of the Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/
